标题
Treatment of gastric adenocarcinoma: a rapidly evolving landscape
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages 113370
出版商
Elsevier BV
发表日期
2023-10-18
DOI
10.1016/j.ejca.2023.113370
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
- (2023) Markus H. Moehler et al. JOURNAL OF CLINICAL ONCOLOGY
- Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.
- (2023) John V. Reynolds et al. JOURNAL OF CLINICAL ONCOLOGY
- INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
- (2023) Nick Pavlakis et al. JOURNAL OF CLINICAL ONCOLOGY
- VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
- (2023) S.Y. Rha et al. ANNALS OF ONCOLOGY
- Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
- (2023) Thorsten O. Goetze et al. INTERNATIONAL JOURNAL OF CANCER
- Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.
- (2023) Shuqiang Yuan et al. JOURNAL OF CLINICAL ONCOLOGY
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
- (2023) Kohei Shitara et al. LANCET
- O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
- (2023) E. Smyth et al. ANNALS OF ONCOLOGY
- ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.
- (2023) Masanori Terashima et al. JOURNAL OF CLINICAL ONCOLOGY
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
- (2023) Manish A. Shah et al. NATURE MEDICINE
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
- (2022) Yoon-Koo Kang et al. LANCET ONCOLOGY
- Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
- (2022) Howard P Safran et al. LANCET ONCOLOGY
- PD‐L1 immunohistochemistry: Clones, cutoffs, and controversies
- (2022) Ivan Chebib et al. APMIS
- MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
- (2022) Yelena Y Janjigian et al. Future Oncology
- Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
- (2022) Weijie Cao et al. Biomarker Research
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2022) F. Lordick et al. ANNALS OF ONCOLOGY
- Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
- (2022) Clélia Coutzac et al. DIGESTIVE AND LIVER DISEASE
- Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
- (2022) Joe Yeong et al. Gastric Cancer
- Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
- (2022) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
- (2022) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
- (2022) Ralf-Dieter Hofheinz et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers in gastric cancer
- (2022) C. Röcken JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
- (2022) Zev A Wainberg et al. LANCET ONCOLOGY
- Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer
- (2022) Harry H. Yoon et al. JAMA Oncology
- Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
- (2022) Kensei Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Current developments in gastric cancer: from molecular profiling to treatment strategy
- (2022) Maria Alsina et al. Nature Reviews Gastroenterology & Hepatology
- Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
- (2021) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
- (2021) Tamara Z. Dabbagh et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
- (2021) Josep Tabernero et al. Future Oncology
- Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
- (2021) Ben M. Eyck et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
- (2021) Soomin Ahn et al. MODERN PATHOLOGY
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
- (2021) Harriet R. Ferguson et al. Cells
- LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
- (2021) E. van Cutsem et al. ANNALS OF ONCOLOGY
- LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
- (2021) J. Xu et al. ANNALS OF ONCOLOGY
- 1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
- (2021) M. Moehler et al. ANNALS OF ONCOLOGY
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
- (2021) Jong-Mu Sun et al. LANCET
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
- (2021) Xiaotian Zhang et al. LANCET ONCOLOGY
- TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
- (2021) Alessandra Raimondi et al. Cancers
- Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction
- (2021) Matthieu Faron et al. EUROPEAN JOURNAL OF CANCER
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- 18F-Fludeoxyglucose–Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer
- (2021) Emma C. Gertsen et al. JAMA Surgery
- Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
- (2020) Juliette Palle et al. DRUGS
- Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
- (2020) Markus H. Moehler et al. JOURNAL OF CLINICAL ONCOLOGY
- VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study
- (2020) Elizabeth Smyth et al. Frontiers in Oncology
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy
- (2020) Katherine I Zhou et al. CLINICAL CANCER RESEARCH
- Gastric cancer
- (2020) Elizabeth C Smyth et al. LANCET
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- (2020) Kohei Shitara et al. JAMA Oncology
- Acquired somatic MMR deficiency is a major cause of MSI tumor in patients suspected for “Lynch-like syndrome” including young patients
- (2020) Cedrick Lefol et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort
- (2020) Daniel R. Principe et al. Scientific Reports
- Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
- (2019) Ugur Sahin et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
- (2019) Yung-Jue Bang et al. Future Oncology
- Testing algorithm for identification of patients with TRK fusion cancer
- (2019) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL PATHOLOGY
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- (2019) Salah-Eddin Al-Batran et al. LANCET
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- Instabilité des microsatellites et cancer
- (2019) Ada Collura et al. M S-MEDECINE SCIENCES
- The 2019 WHO classification of tumours of the digestive system
- (2019) Iris D. Nagtegaal et al. HISTOPATHOLOGY
- Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
- (2019) Filippo Pietrantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
- (2019) Li-Tzong Chen et al. Gastric Cancer
- P-089Gastric cancer in Lynch Syndrome: Are precancerous conditions co- risk factors?
- (2018) M Fornasarig et al. ANNALS OF ONCOLOGY
- Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
- (2018) J Adam et al. ANNALS OF ONCOLOGY
- Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)
- (2018) Aziz Zaanan et al. DIGESTIVE AND LIVER DISEASE
- Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)
- (2018) Aziz Zaanan et al. DIGESTIVE AND LIVER DISEASE
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- 83POlaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
- (2018) Y-Z Liu et al. ANNALS OF ONCOLOGY
- Immunotherapy in advanced gastric cancer, is it the future?
- (2018) C. Coutzac et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- Gastric adenocarcinoma
- (2017) Jaffer A. Ajani et al. Nature Reviews Disease Primers
- Mismatch Repair Deficiency, Microsatellite Instability, and Survival
- (2017) Elizabeth C. Smyth et al. JAMA Oncology
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
- (2017) Lihu Gu et al. PLoS One
- Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant
- (2016) Jun Li et al. AMERICAN JOURNAL OF HUMAN GENETICS
- ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
- (2016) Jens Hoeppner et al. BMC CANCER
- The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015
- (2016) Giovanni De Manzoni et al. Gastric Cancer
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
- (2016) Sarah Derks et al. Oncotarget
- TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
- (2015) Trevor Leong et al. BMC CANCER
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
- (2015) Joel Shapiro et al. LANCET ONCOLOGY
- Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
- (2015) Razvan Cristescu et al. NATURE MEDICINE
- Familial Gastric Cancers
- (2015) N. Setia et al. ONCOLOGIST
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Correction: An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers
- (2014) Ajay Goel et al. PLoS One
- Differential clinicopathologic features in microsatellite-unstable gastric cancers with and without MLH1 methylation
- (2012) Kyung-Ju Kim et al. HUMAN PATHOLOGY
- Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas
- (2012) William K. Funkhouser et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- HER2 testing in gastric cancer: a practical approach
- (2012) Josef Rüschoff et al. MODERN PATHOLOGY
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
- (2012) P. van Hagen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gastric cancer in individuals with Li-Fraumeni syndrome
- (2011) Serena Masciari et al. GENETICS IN MEDICINE
- Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
- (2011) Marc Ychou et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma
- (2010) Fei Bao et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
- (2010) Ilfet Songun et al. LANCET ONCOLOGY
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- MUTYH-associated polyposis
- (2009) Julian R. Sampson et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
- (2009) J D Barros-Silva et al. BRITISH JOURNAL OF CANCER
- Germline CDH1 deletions in hereditary diffuse gastric cancer families
- (2009) C. Oliveira et al. HUMAN MOLECULAR GENETICS
- Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer
- (2009) William H. Allum et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction
- (2009) Michael Stahl et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started